Maladaptive Plasticity in Levodopa-Induced Dyskinesias and Tardive Dyskinesias: Old and New Insights on the Effects of Dopamine Receptor Pharmacology

Maladaptive plasticity can be defined as behavioral loss or even development of disease symptoms resulting from aberrant plasticity changes in the human brain. Hyperkinetic movement disorders, in the neurological or psychiatric realms, have been associated with maladaptive neural plasticity that can be expressed by functional changes such as an increase in transmitter release, receptor regulation, and synaptic plasticity or anatomical modifications such as axonal regeneration, sprouting, synaptogenesis, and neurogenesis. Recent evidence from human and animal models provided support to the hypothesis that these phenomena likely depend on altered dopamine turnover induced by long-term drug treatment. However, it is still unclear how and where these altered mechanisms of cortical plasticity may be localized. This study provides an up-to-date overview of these issues together with some reflections on future studies in the field, particularly focusing on two specific disorders (levodopa-induced dyskinesias in Parkinson’s disease patients and tardive dyskinesias in schizophrenic patients) where the modern neuroimaging approaches have recently provided new fundamental insights.

[1]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[2]  J. Sigwald,et al.  [4 Cases of facio-bucco-linguo-masticatory dyskinesis of prolonged development following treatment with neuroleptics]. , 1959, Revue neurologique.

[3]  R. Baldessarini,et al.  Mechanisms underlying tardive dyskinesia. , 1976, Research publications - Association for Research in Nervous and Mental Disease.

[4]  C. Marsden,et al.  The pathophysiology of extrapyramidal side-effects of neuroleptic drugs , 1980, Psychological Medicine.

[5]  A J Cross,et al.  Abnormal Involuntary Movements in Schizophrenia: Are They Related to the Disease Process or Its Treatment? Are They Associated with Changes in Dopamine Receptors? , 1982, Journal of clinical psychopharmacology.

[6]  Current psychopathological theories of tardive dyskinesia and their implications for future research. , 1982, Neuropsychobiology.

[7]  B. Pakkenberg,et al.  Post-mortem Study of Chronic Schizophrenic Brains , 1987, British Journal of Psychiatry.

[8]  T. Crow,et al.  Schizophrenia as an anomaly of development of cerebral asymmetry. A postmortem study and a proposal concerning the genetic basis of the disease. , 1989, Archives of general psychiatry.

[9]  Eka Swadiansa The hypothesis , 1990 .

[10]  P. Calabresi,et al.  Chronic neuroleptic treatment: D2 dopamine receptor supersensitivity and striatal glutamatergic transmission , 1992, Annals of neurology.

[11]  J. Jankovic,et al.  Tardive syndromes and other drug-induced movement disorders. , 1995, Clinical neuropharmacology.

[12]  W M Jenkins,et al.  A primate genesis model of focal dystonia and repetitive strain injury , 1996, Neurology.

[13]  D. Dexter,et al.  Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease. , 1996, Free radical research.

[14]  S. Heckers,et al.  Neuropathology of schizophrenia: cortex, thalamus, basal ganglia, and neurotransmitter-specific projection systems. , 1997, Schizophrenia bulletin.

[15]  U Sabatini,et al.  Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. , 1998, Brain : a journal of neurology.

[16]  K. Jellinger,et al.  The neuropathology of schizophrenia. , 1999, Journal of neuropathology and experimental neurology.

[17]  B. McEwen Stress and hippocampal plasticity. , 1999, Annual review of neuroscience.

[18]  The neuropathology of schizophrenia. , 1999, Journal of neuropathology and experimental neurology.

[19]  G Bernardi,et al.  Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? , 2000, Annals of neurology.

[20]  D E Casey,et al.  Tardive dyskinesia: pathophysiology and animal models. , 2000, The Journal of clinical psychiatry.

[21]  J. Obeso,et al.  Pathophysiology of the basal ganglia in Parkinson's disease , 2000, Trends in Neurosciences.

[22]  D J Brooks,et al.  Neuroimaging of dyskinesia. , 2000, Annals of neurology.

[23]  Vesna Sossi,et al.  Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover , 2001 .

[24]  M Schulzer,et al.  Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. , 2001, Annals of neurology.

[25]  A. Nambu,et al.  Functional significance of the cortico–subthalamo–pallidal ‘hyperdirect’ pathway , 2002, Neuroscience Research.

[26]  T. Robbins,et al.  Inhibition and the right inferior frontal cortex , 2004, Trends in Cognitive Sciences.

[27]  D. Casey Pathophysiology of antipsychotic drug-induced movement disorders. , 2004, The Journal of clinical psychiatry.

[28]  D. Calne,et al.  Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. , 2004, Brain : a journal of neurology.

[29]  T. Robbins,et al.  Cognitive Inflexibility After Prefrontal Serotonin Depletion , 2004, Science.

[30]  C. Tanner,et al.  Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.

[31]  P. Calabresi,et al.  Pathological synaptic plasticity in the striatum: implications for Parkinson's disease. , 2005, Neurotoxicology.

[32]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[33]  C Caltagirone,et al.  rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease , 2005, Neurology.

[34]  Francesca Morgante,et al.  Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. , 2006, Brain : a journal of neurology.

[35]  J. Rothwell,et al.  Task-specific hand dystonia: can too much plasticity be bad for you? , 2006, Trends in Neurosciences.

[36]  Carles Falcon,et al.  Brain T1 intensity changes after levodopa administration in healthy subjects: a voxel-based morphometry study. , 2006, British journal of clinical pharmacology.

[37]  M. Cenci Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia , 2007, Trends in Neurosciences.

[38]  Anders Björklund,et al.  Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. , 2007, Brain : a journal of neurology.

[39]  Karl J. Friston,et al.  Voxel-Based Morphometry , 2015 .

[40]  M. Hallett,et al.  The pathophysiological basis of dystonias , 2008, Nature Reviews Neuroscience.

[41]  C. Caltagirone,et al.  Cerebellar magnetic stimulation decreases levodopa-induced dyskinesias in Parkinson disease , 2009, Neurology.

[42]  Wei-Ho Chung,et al.  Probabilistic Model , 2009, Encyclopedia of Database Systems.

[43]  L. Descarries,et al.  Maladaptive plasticity of serotonin axon terminals in levodopa‐induced dyskinesia , 2010, Annals of neurology.

[44]  C. Caltagirone,et al.  Morphological correlates of MAO A VNTR polymorphism: New evidence from cortical thickness measurement , 2010, Behavioural Brain Research.

[45]  G. Koch rTMS effects on levodopa induced dyskinesias in Parkinson's disease patients: searching for effective cortical targets. , 2010, Restorative neurology and neuroscience.

[46]  C. Konradi,et al.  Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. , 2010, Progress in brain research.

[47]  V. Peralta,et al.  Motor behavior abnormalities in drug‐naïve patients with schizophrenia spectrum disorders , 2010, Movement disorders : official journal of the Movement Disorder Society.

[48]  K. Hisanaga,et al.  Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial , 2010, PloS one.

[49]  T. Zesiewicz Parkinson disease: The controversy of levodopa toxicity in Parkinson disease , 2011, Nature Reviews Neurology.

[50]  Antonio Cerasa,et al.  Increased prefrontal volume in PD with levodopa‐induced dyskinesias: A voxel‐based morphometry study , 2011, Movement disorders : official journal of the Movement Disorder Society.

[51]  M. Aminoff,et al.  Therapies for dopaminergic‐induced dyskinesias in parkinson disease , 2011, Annals of neurology.

[52]  Alexander Hammers,et al.  Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. , 2011, Brain : a journal of neurology.

[53]  E. Bézard,et al.  Molecular mechanisms of l-DOPA-induced dyskinesia. , 2011, International review of neurobiology.

[54]  Do levodopa treatments modify the morphology of the parkinsonian brain? , 2012, Movement disorders : official journal of the Movement Disorder Society.

[55]  M. Edwards,et al.  Tardive dyskinesia is caused by maladaptive synaptic plasticity: A hypothesis , 2012, Movement disorders : official journal of the Movement Disorder Society.

[56]  M. Cenci,et al.  Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease , 2012, Progress in Neurobiology.

[57]  S. Kapur,et al.  Contrasting Effects of Haloperidol and Lithium on Rodent Brain Structure: A Magnetic Resonance Imaging Study with Postmortem Confirmation , 2012, Biological Psychiatry.

[58]  S. Meunier,et al.  Acute dopamine boost has a negative effect on plasticity of the primary motor cortex in advanced Parkinson's disease. , 2012, Brain : a journal of neurology.

[59]  Adam R. Aron,et al.  Is executive control used to compensate for involuntary movements in levodopa‐induced dyskinesia? , 2012, Movement disorders : official journal of the Movement Disorder Society.

[60]  A. Cerasa,et al.  Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias. , 2013, Parkinsonism & related disorders.

[61]  A. Cerasa,et al.  Prefrontal thickening in PD with levodopa-induced dyskinesias: new evidence from cortical thickness measurement. , 2013, Parkinsonism & related disorders.

[62]  E. Castrén,et al.  Neuronal plasticity and antidepressant actions , 2013, Trends in Neurosciences.

[63]  Cheng-Ta Li,et al.  Gray Matter Abnormalities in Schizophrenia Patients with Tardive Dyskinesia: A Magnetic Resonance Imaging Voxel-Based Morphometry Study , 2013, PloS one.

[64]  S. Meunier,et al.  Cerebellar sensory processing alterations impact motor cortical plasticity in Parkinson's disease: clues from dyskinetic patients. , 2014, Cerebral cortex.

[65]  A. Cerasa,et al.  May Hyperdirect Pathway Be a Plausible Neural Substrate for Understanding the rTMS-related Effects on PD Patients With Levodopa-induced Dyskinesias? , 2014, Brain Stimulation.

[66]  P. Haggard,et al.  Prefrontal cortex volume reductions and tic inhibition are unrelated in uncomplicated GTS adults. , 2014, Journal of psychosomatic research.

[67]  David A. Lewis,et al.  Implications for Parkinson ' s Disease , 2022 .